Company Description
Replidyne wants to stop bad bacteria from replicating. Its lead product candidate, faropenem medoxomil, is an oral antibiotic that the...
Key Replidyne Financials
| Company Type | Public - NASDAQ (GM): RDYN Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $58.6 |
| 2006 Employees | 85 |
More Replidyne Financials (8 pages)
Competition
Competitive Landscape for Chemicals
Demand is driven by the health of the US economy because chemicals are used to make a wide variety of industrial and consumer products. The profitability of individual companies is closely tied to...
Read more about Replidyne's competition across multiple industries
Top Replidyne Competitors
Sponsored Links
The Business Directory
Replidyne Executives
| Title | Name & Bio | Contact |
|---|---|---|
| President, CEO, and Director | Kenneth J. Collins | Network | E-mail |
| CFO and Treasurer | Mark L. Smith | Network | E-mail |
| SVP, Corporate Development | Donald J. Morrissey Jr. | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Sponsored Opportunity
